TCGA-A2-A0ER-01A-21R-A034-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 75
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.520
- MITOTIC_SPINDLE+0.400
- E2F_TARGETS+0.380
- ESTROGEN_RESPONSE_EARLY+0.370
- ESTROGEN_RESPONSE_LATE+0.350
- G2M_CHECKPOINT+0.350
- BILE_ACID_METABOLISM+0.280
- ANDROGEN_RESPONSE+0.260
- HEME_METABOLISM+0.260
- OXIDATIVE_PHOSPHORYLATION+0.230
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.450
- MYC_TARGETS_V2-0.380
- INTERFERON_GAMMA_RESPONSE-0.340
- INTERFERON_ALPHA_RESPONSE-0.320
- ALLOGRAFT_REJECTION-0.300
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.280
- NOTCH_SIGNALING-0.250
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.200
- HEDGEHOG_SIGNALING-0.180
- KRAS_SIGNALING_UP-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BT-A3PH-01A-11R-A220-07 | — | — | 0.797 |
| 2 | SRR12202419 | — | — | 0.786 |
| 3 | TCGA-E2-A155-01A-11R-A12D-07 | — | B | 0.777 |
| 4 | MBCProject_0946_T1_RNA | — | C | 0.771 |
| 5 | TCGA-A2-A25E-01A-11R-A169-07 | — | B | 0.760 |
| 6 | SRR8942954 | — | — | 0.758 |
| 7 | SRR25617890 | — | B | 0.757 |
| 8 | TCGA-B6-A0WV-01A-11R-A109-07 | — | B | 0.753 |
| 9 | TCGA-A2-A1G4-01A-11R-A13Q-07 | — | B | 0.752 |
| 10 | MNG775 | — | — | 0.748 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.520 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.370 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.350 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.260 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.260 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.230 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.230 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.220 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.200 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.180 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| APOPTOSIS | 0.170 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.160 | Inavolisib | — uncovered |